Literature DB >> 6158371

Effect of human leukocyte interferon on the metastatic lung tumor of osteosarcoma: case reports.

H Ito, K Murakami, T Yanagawa, S Ban, H Sawamura, K Sakakida, A Matsuo, J Imanishi, T Kishida.   

Abstract

Three patients with pulmonary metastases of osteosarcoma underwent treatment with intravenous or intramuscular administration of human leukocyte interferon. In 2 cases, the size of the metastasized tumor mass diminished temporarily six or eight months after interferon treatment, and serum alkaline phosphatase levels decreased to normal. In 1 case, the tumor cell from the pleural exudate 1 could be isolated and cultivated in vitro. When 2,000 IU of interferon was added to the tumor cell culture, marked inhibition of tumor cell growth resulted. In the other case, interferon had no effect on the metastasized lung tumor.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6158371     DOI: 10.1002/1097-0142(19801001)46:7<1562::aid-cncr2820460711>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Interferons and interferon inducers: development of clinical usefulness and therapeutic promise.

Authors:  R B Pollard
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

2.  Gamma interferon down-regulates glucocorticoid receptor expression and attenuates hormone action in a human osteosarcoma cell line.

Authors:  L N Song
Journal:  Endocrine       Date:  1995-10       Impact factor: 3.633

3.  Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy.

Authors:  L Tentori; M P Fuggetta; S D'Atri; A Aquino; C Nunziata; M Roselli; P Ballatore; E Bonmassar; L De Vecchis
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study.

Authors:  K Winkler; G Beron; R Kotz; M Salzer-Kuntschik; J Beck; W Beck; W Brandeis; W Ebell; R Erttmann; U Göbel; W Havers; G Henze; L Hinderfield; P Höcker; A Jobke; H Jürgens; H Kabisch; G Landbeck; P Preusser; G Prindull; W Ramach; J Ritter; J Sekera; J Treuner; G Wüst
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

5.  Immune-based therapies for sarcoma.

Authors:  Seth M Pollack; Elizabeth T Loggers; Eve T Rodler; Cassian Yee; Robin L Jones
Journal:  Sarcoma       Date:  2011-01-23

6.  Immunotherapeutic Intervention against Sarcomas.

Authors:  Paolo Pedrazzoli; Simona Secondino; Vittorio Perfetti; Patrizia Comoli; Daniela Montagna
Journal:  J Cancer       Date:  2011-06-13       Impact factor: 4.207

Review 7.  Immunotherapy for Bone and Soft Tissue Sarcomas.

Authors:  Takenori Uehara; Tomohiro Fujiwara; Ken Takeda; Toshiyuki Kunisada; Toshifumi Ozaki; Heiichiro Udono
Journal:  Biomed Res Int       Date:  2015-06-17       Impact factor: 3.411

Review 8.  Sarcoma immunotherapy: past approaches and future directions.

Authors:  S P D'Angelo; W D Tap; G K Schwartz; R D Carvajal
Journal:  Sarcoma       Date:  2014-03-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.